Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01117012 · ClinicalTrials.gov registry record · Phase 3
Rollover Study of VX-770 in Cystic Fibrosis Subjects
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT01117012 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 192 participants.
The verdict
NCT01117012, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate the safety of long-term VX-770 treatment in participants with cystic fibrosis (CF). The secondary objective of the study was to evaluate the efficacy of long-term VX-770 treatment in subjects with CF.
Interventions
- DRUG Ivacaftor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01117012
The ClinicalTrials.gov registry entry for NCT01117012 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ivacaftor is the first listed.
NCT01117012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01117012 about?
NCT01117012 is a clinical study titled "Rollover Study of VX-770 in Cystic Fibrosis Subjects". The primary objective of the study was to evaluate the safety of long-term VX-770 treatment in participants with cystic fibrosis (CF). The secondary objective of the study was to evaluate the efficacy of long-term VX-770 treatment in subjects with CF.
What is the current status of trial NCT01117012?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2010-07. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01117012?
The interventions under investigation include: Ivacaftor (DRUG).
Who is sponsoring clinical trial NCT01117012?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.